- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Clinical and Developmental Immunology
Volume 2013 (2013), Article ID 965841, 7 pages
N-Terminal Plasmodium vivax Merozoite Surface Protein-1, a Potential Subunit for Malaria Vivax Vaccine
1Universidade Federal do Amazonas, Avenida General Rodrigo Octávio Jordão Ramos 3000, Campus Universitário, Coroado I, 69077-000 Manaus, AM, Brazil
2Instituto Leônidas e Maria Deane-Fiocruz, Rua Teresina 476, 69057-070 Manaus, AM, Brazil
Received 24 April 2013; Accepted 14 August 2013
Academic Editor: Wuelton Marcelo Monteiro
Copyright © 2013 Fernanda G. Versiani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- M. V. Lacerda, M. P. Mourão, M. A. Alexandre et al., “Understanding the clinical spectrum of complicated Plasmodium vivax malaria: a systematic review on the contributions of the Brazilian literature,” Malaria Journal, vol. 11, article 12, 2012.
- I. Mueller, M. R. Galinski, J. K. Baird et al., “Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite,” The Lancet Infectious Diseases, vol. 9, no. 9, pp. 555–566, 2009.
- R. N. Price, N. M. Douglas, and N. M. Anstey, “New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance,” Current Opinion in Infectious Diseases, vol. 22, no. 5, pp. 430–435, 2009.
- E. Tjitra, N. M. Anstey, P. Sugiarto et al., “Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia,” PLoS Medicine, vol. 5, no. 6, pp. 0890–0899, 2008.
- S. J. Rogerson and R. Carter, “Severe vivax malaria: newly recognised or rediscovered?” PLoS Medicine, vol. 5, no. 6, pp. 0875–0877, 2008.
- F. T. Costa, S. C. Lopes, L. Albrecht et al., “On the pathogenesis of Plasmodium vivax malaria: perspectives from the Brazilian field,” International Journal for Parasitology, vol. 42, no. 12, pp. 1099–1105, 2012.
- B. O. Carvalho, S. C. P. Lopes, P. A. Nogueira et al., “On the cytoadhesion of Plasmodium vivax-infected erythrocytes,” Journal of Infectious Diseases, vol. 202, no. 4, pp. 638–647, 2010.
- F. Lu, B. Wang, J. Cao et al., “Prevalence of drug resistance-associated gene mutations in Plasmodium vivax in Central China,” The Korean Journal of Parasitology, vol. 50, no. 4, pp. 379–384, 2012.
- S. Garg, V. Saxena, V. Lumb et al., “Novel mutations in the antifolate drug resistance marker genes among Plasmodium vivax isolates exhibiting severe manifestations,” Experimental Parasitology, vol. 132, no. 4, pp. 410–416, 2012.
- C. V.-R. Rdel, M. S. Bastos, M. J. Menezes, P. Orjuela-Sanchez, and M. U. Ferreira, “Single-nucleotide polymorphism and copy number variation of the multidrug resistance-1 locus of Plasmodium vivax: local and global patterns,” The American Journal of Tropical Medicine and Hygiene, vol. 87, no. 5, pp. 813–821, 2012.
- D. H. Kerlin, K. Boyce, J. Marfurt et al., “An analytical method for assessing stage-specific drug activity in Plasmodium vivax malaria: implications for ex vivo drug susceptibility testing,” PLOS Neglected Tropical Diseases, vol. 6, no. 8, Article ID e1772, 2012.
- J. Marfurt, F. Chalfein, P. Prayoga et al., “Comparative ex vivo activity of novel endoperoxides in multidrug-resistant Plasmodium falciparum and P. vivax,” Antimicrobial Agents and Chemotherapy, vol. 56, no. 10, pp. 5258–5263, 2012.
- A. C. Aguiar, M. Santos Rde, F. J. Figueiredo et al., “Antimalarial activity and mechanisms of action of two novel 4-aminoquinolines against chloroquine-resistant parasites,” PLoS One, vol. 7, no. 5, Article ID e37259, 2012.
- J. K. Baird, “Resistance to chloroquine unhinges vivax malaria therapeutics,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 5, pp. 1827–1830, 2011.
- B. E. Gama, M. V. G. Lacerda, C. T. Daniel-Ribeiro, and M. D. F. Ferreira-da-Cruz, “Chemoresistance of Plasmodium falciparum and Plasmodium vivax parasites in Brazil: consequences on disease morbidity and control,” Memorias do Instituto Oswaldo Cruz, vol. 106, no. 1, pp. 159–166, 2011.
- M. A. Alexandre, C. O. Ferreira, A. M. Siqueira et al., “Severe Plasmodium vivax malaria, Brazilian Amazon,” Emerging Infectious Diseases, vol. 16, no. 10, pp. 1611–1614, 2010.
- M. R. Galinski and J. W. Barnwell, “Plasmodium vivax: who cares?” Malaria Journal, vol. 7, no. 1, article S9, 2008.
- S. Herrera, G. Corradin, and M. Arévalo-Herrera, “An update on the search for a Plasmodium vivax vaccine,” Trends in Parasitology, vol. 23, no. 3, pp. 122–128, 2007.
- G. D. Weedall and D. J. Conway, “Detecting signatures of balancing selection to identify targets of anti-parasite immunity,” Trends in Parasitology, vol. 26, no. 7, pp. 363–369, 2010.
- S. L. Takala, D. Coulibaly, M. A. Thera et al., “Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development,” Science translational medicine, vol. 1, no. 2, p. 2, 2009.
- I. Mueller, V. S. Moorthy, G. V. Brown, P. G. Smith, P. Alonso, and B. Genton, “Guidance on the evaluation of Plasmodium vivax vaccines in populations exposed to natural infection,” Vaccine, vol. 27, no. 41, pp. 5633–5643, 2009.
- S. Cheesman, E. O'Mahony, S. Pattaradilokrat, K. Degnan, S. Knott, and R. Carter, “A single parasite gene determines strain-specific protective immunity against malaria: the role of the merozoite surface protein I,” International Journal for Parasitology, vol. 40, no. 8, pp. 951–961, 2010.
- M. Arévalo-Herrera and S. Herrera, “Plasmodium vivax malaria vaccine development,” Molecular Immunology, vol. 38, no. 6, pp. 443–455, 2001.
- Y. Cheng, Y. Wang, D. Ito, et al., “The Plasmodium vivax merozoite surface protein 1 paralog is a novel erythrocyte-binding ligand of P. vivax,” Infect Immun, vol. 81, no. 5, pp. 1585–1595, 2013.
- S. Sachdeva, G. Ahmad, P. Malhotra, P. Mukherjee, and V. S. Chauhan, “Comparison of immunogenicities of recombinant Plasmodium vivax merozoite surface protein 1 19- and 42-kilodalton fragments expressed in Escherichia coli,” Infection and Immunity, vol. 72, no. 10, pp. 5775–5782, 2004.
- D. Y. Bargieri, D. S. Rosa, M. A. S. Lasaro, L. C. S. Ferreira, I. S. Soares, and M. M. Rodrigues, “Adjuvant requirement for successful immunization with recombinant derivatives of Plasmodium vivax merozoite surface protein-1 delivered via the intranasal route,” Memorias do Instituto Oswaldo Cruz, vol. 102, no. 3, pp. 313–317, 2007.
- D. Y. Bargieri, D. S. Rosa, C. J. M. Braga et al., “New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin,” Vaccine, vol. 26, no. 48, pp. 6132–6142, 2008.
- S. Parween, P. K. Gupta, and V. S. Chauhan, “Induction of humoral immune response against PfMSP-119 and PvMSP-119 using gold nanoparticles along with alum,” Vaccine, vol. 29, no. 13, pp. 2451–2460, 2011.
- C. Yang, W. E. Collins, J. S. Sullivan, D. C. Kaslow, L. Xiao, and A. A. Lal, “Partial protection against Plasmodium vivax blood-stage infection in Saimiri monkeys by immunization with a recombinant C-terminal fragment of merozoite surface protein 1 in block copolymer adjuvant,” Infection and Immunity, vol. 67, no. 1, pp. 342–349, 1999.
- S. Dutta, D. C. Kaushal, L. A. Ware et al., “Merozoite surface protein 1 of Plasmodium vivax induces a protective response against Plasmodium cynomolgi challenge in rhesus monkeys,” Infection and Immunity, vol. 73, no. 9, pp. 5936–5944, 2005.
- A. Valderrama-Aguirre, G. Quintero, A. Gómez et al., “Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 Pv200L: a potential malaria vaccine subunit,” American Journal of Tropical Medicine and Hygiene, vol. 73, no. 5, pp. 16–24, 2005.
- R. D. Ellis, Y. Wu, L. B. Martin, et al., “Phase 1 study in malaria naive adults of BSAM2/Alhydrogel(R)+CPG, 7909, a blood stage vaccine against P. falciparum malaria,” PLoS One, vol. 7, no. 10, Article ID e46094, 2012.
- E. S. Bergmann-Leitner, E. H. Duncan, R. M. Mease, and E. Angov, “Impact of pre-existing MSP1(42)-allele specific immunity on potency of an erythrocytic Plasmodium falciparum vaccine,” Malaria Journal, vol. 11, p. 315, 2012.
- D. K. Moss, E. J. Remarque, B. W. Faber et al., “Plasmodium falciparum 19-kilodalton merozoite surface protein 1 (MSP1)-specific antibodies that interfere with parasite growth in vitro can inhibit MSP1 processing, merozoite invasion, and intracellular parasite development,” Infection and Immunity, vol. 80, no. 3, pp. 1280–1287, 2012.
- S. H. Sheehy, C. J. A. Duncan, S. C. Elias et al., “Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors,” Molecular Therapy, vol. 19, no. 12, pp. 2269–2276, 2011.
- E. Malkin, C. A. Long, A. W. Stowers et al., “Phase 1 study of two merozoite surface protein 1 (MSP142) vaccines for Plasmodium falciparum malaria,” PLoS Clinical Trials, vol. 2, no. 4, article e12, 2007.
- M. R. Withers, D. McKinney, B. R. Ogutu et al., “Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children,” PLOS Clinical Trials, vol. 1, no. 7, article e32, 2006.
- M. S. Bastos, M. Da Silva-Nunes, R. S. Malafronte et al., “Antigenic polymorphism and naturally acquired antibodies to Plasmodium vivax merozoite surface protein 1 in rural Amazonians,” Clinical and Vaccine Immunology, vol. 14, no. 10, pp. 1249–1259, 2007.
- H. A. Del Portillo, S. Longacre, E. Khouri, and P. H. David, “Primary structure of the merozoite surface antigen 1 of Plasmodium vivax reveals sequences conserved between different Plasmodium species,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 9, pp. 4030–4034, 1991.
- C. Putaporntip, S. Jongwutiwes, N. Sakihama et al., “Mosaic organization and heterogeneity in frequency of allelic recombination of the Plasmodium vivax merozoite surface protein-1 locus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 25, pp. 16348–16353, 2002.
- M. E. M. Almeida, F. G. Versiani, L. A. Soares, et al., “Repertoire of proteins of PvMSP1 Block 2 able to broaden protective and serotype-specific IgG3 antibodies,” In press.
- F. G. Versiani, M. E. M. Almeida, C. M. Gisely, et al., “High levels of IgG3 anti ICB2-5 in Plasmodium vivax-infected individuals who did not develop symptoms,” Malaria Journal, vol. 12, article 294, 2013.
- K. Koussis, C. Withers-Martinez, S. Yeoh et al., “A multifunctional serine protease primes the malaria parasite for red blood cell invasion,” EMBO Journal, vol. 28, no. 6, pp. 725–735, 2009.
- M. Kadekoppala and A. A. Holder, “Merozoite surface proteins of the malaria parasite: the MSP1 complex and the MSP7 family,” International Journal for Parasitology, vol. 40, no. 10, pp. 1155–1161, 2010.
- A. A. Holder, “Malaria vaccines: where next?” PLoS Pathogens, vol. 5, no. 10, Article ID e1000638, 2009.
- J. J. Babon, W. D. Morgan, G. Kelly, J. F. Eccleston, J. Feeney, and A. A. Holder, “Structural studies on Plasmodium vivax merozoite surface protein-1,” Molecular and Biochemical Parasitology, vol. 153, no. 1, pp. 31–40, 2007.
- A. A. Holder, M. J. Blackman, P. A. Burghaus et al., “A malaria merozoite surface protein (MSP1)-structure, processing and function,” Memorias do Instituto Oswaldo Cruz, vol. 87, pp. 37–42, 1992.
- K. Tanabe, M. Mackay, M. Goman, and J. G. Scaife, “Allelic dimorphism in a surface antigen gene of the malaria parasite Plasmodium falciparum,” Journal of Molecular Biology, vol. 195, no. 2, pp. 273–287, 1987.
- G. N. Kiwanuka, “Genetic diversity in Plasmodium falciparum merozoite surface protein 1 and 2 coding genes and its implications in malaria epidemiology: a review of published studies from 1997–2007,” Journal of Vector Borne Diseases, vol. 46, no. 1, pp. 1–12, 2009.
- C. Putaporntip, S. Jongwutiwes, T. Iwasaki, H. Kanbara, and A. L. Hughes, “Ancient common ancestry of the merozoite surface protein 1 of Plasmodium vivax as inferred from its homologue in Plasmodium knowlesi,” Molecular and Biochemical Parasitology, vol. 146, no. 1, pp. 105–108, 2006.
- I. S. Soares, G. Levitus, J. M. Souza, H. A. Del Portillo, and M. M. Rodrigues, “Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria,” Infection and Immunity, vol. 65, no. 5, pp. 1606–1614, 1997.
- I. S. Soares, M. G. Da Cunha, M. N. Silva, J. M. Souza, H. A. Del Portillo, and M. M. Rodrigues, “Longevity of naturally acquired antibody responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1,” American Journal of Tropical Medicine and Hygiene, vol. 60, no. 3, pp. 357–363, 1999.
- G. Levitus, F. Mertens, M. A. Speranca, L. M. A. Camargo, M. U. Ferreira, and H. A. Del Portillo, “Characterization of naturally acquired human IgG responses against the N-terminal region of the merozoite surface protein 1 of Plasmodium vivax,” American Journal of Tropical Medicine and Hygiene, vol. 51, no. 1, pp. 68–76, 1994.
- P. A. Nogueira, F. P. Alves, C. Fernandez-Becerra et al., “A reduced risk of infection with Plasmodium vivax and clinical protection against malaria are associated with antibodies against the N terminus but not the C terminus of merozoite surface protein 1,” Infection and Immunity, vol. 74, no. 5, pp. 2726–2733, 2006.
- C. Fernandez-Becerra, S. Sanz, M. Brucet et al., “Naturally-acquired humoral immune responses against the N- and C-termini of the Plasmodium vivax MSP1 protein in endemic regions of Brazil and Papua New Guinea using a multiplex assay,” Malaria Journal, vol. 9, no. 1, article 29, 2010.
- L. M. Storti-Melo, W. C. Souza-Neiras, G. C. Cassiano et al., “Evaluation of the naturally acquired antibody immune response to the Pv 200L N-terminal fragment of Plasmodium vivax merozoite surface protein-1 in four areas of the Amazon Region of Brazil,” American Journal of Tropical Medicine and Hygiene, vol. 84, no. 2 S, pp. 58–63, 2011.
- G. Levitus and H. A. del Portillo, “Advances toward the development of an asexual blood stage MSP-1 vaccine of Plasmodium vivax,” Memorias do Instituto Oswaldo Cruz, vol. 89, supplement 2, pp. 81–84, 1994.
- F. Mertens, G. Levitus, L.-M. A. Camargo, M. U. Ferreira, A. P. Dutra, and H. A. Del Portillo, “Longitudinal study of naturally acquired humoral immune responses against the merozoite surface protein 1 of Plasmodium vivax in patients from Rondonia, Brazil,” American Journal of Tropical Medicine and Hygiene, vol. 49, no. 3, pp. 383–392, 1993.
- D. R. Cavanagh, D. Dodoo, L. Hviid et al., “Antibodies to the N-terminal block 2 of Plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria,” Infection and Immunity, vol. 72, no. 11, pp. 6492–6502, 2004.
- G. J. M. Cowan, A. M. Creasey, K. Dhansarnsombut, A. W. Thomas, E. J. Remarque, and D. R. Cavanagh, “A malaria vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune response,” PLoS One, vol. 6, no. 10, Article ID e26616, 2011.
- K. K. A. Tetteh and D. J. Conway, “A polyvalent hybrid protein elicits antibodies against the diverse allelic types of block 2 in Plasmodium falciparum merozoite surface protein 1,” Vaccine, vol. 29, no. 44, pp. 7811–7817, 2011.